published meta-analysis   sensitivity analysis   studies

tocilizumab in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsBACC Bay Tocilizumab Trial, 2020 1.52 [0.41; 5.62] CORIMUNO-19, 2020 0.92 [0.31; 2.71] COVACTA (Rosas), 2020 1.02 [0.62; 1.68] EMPACTA, 2020 1.13 [0.54; 2.40] RCT-TCZ-COVID-19, 2021 2.24 [0.20; 25.37] REMAP-CAP tocilizumab, 2021 0.70 [0.51; 0.95] 0.84[0.66; 1.06]BACC Bay Tocilizumab Trial, 2020, CORIMUNO-19, 2020, COVACTA (Rosas), 2020, EMPACTA, 2020, RCT-TCZ-COVID-19, 2021, REMAP-CAP tocilizumab, 202160%2,060moderateserious clinical deteriorationdetailed resultsBACC Bay Tocilizumab Trial, 2020 1.11 [0.59; 2.09] CORIMUNO-19, 2020 0.56 [0.26; 1.20] EMPACTA, 2020 0.55 [0.33; 0.92] RCT-TCZ-COVID-19, 2021 1.05 [0.59; 1.86] 0.78[0.53; 1.14]BACC Bay Tocilizumab Trial, 2020, CORIMUNO-19, 2020, EMPACTA, 2020, RCT-TCZ-COVID-19, 2021436%495moderatenot evaluable clinical improvementdetailed resultsBACC Bay Tocilizumab Trial, 2020 1.06 [0.80; 1.41] COVACTA (Rosas), 2020 1.19 [0.81; 1.75] EMPACTA, 2020 1.15 [0.90; 1.47] REMAP-CAP tocilizumab, 2021 1.64 [1.25; 2.15] 1.25[1.02; 1.52]BACC Bay Tocilizumab Trial, 2020, COVACTA (Rosas), 2020, EMPACTA, 2020, REMAP-CAP tocilizumab, 2021448%1,435moderatenot evaluable clinical improvement (28-day)detailed resultsCOVACTA (Rosas), 2020 1.19 [0.81; 1.75] 1.19[0.81; 1.75]COVACTA (Rosas), 202010%438moderatenot evaluable clinical improvement (time to event analysis only)detailed resultsEMPACTA, 2020 1.15 [0.90; 1.47] 1.15[0.90; 1.47]EMPACTA, 202010%moderatenot evaluable death or ventilationdetailed resultsBACC Bay Tocilizumab Trial, 2020 0.83 [0.38; 1.81] CORIMUNO-19, 2020 0.56 [0.24; 1.31] EMPACTA, 2020 0.56 [0.32; 0.97] 0.62[0.42; 0.93]BACC Bay Tocilizumab Trial, 2020, CORIMUNO-19, 2020, EMPACTA, 202030%373moderatenot evaluable hospital dischargedetailed resultsEMPACTA, 2020 1.16 [0.90; 1.49] 1.16[0.90; 1.49]EMPACTA, 202010%moderatenot evaluable ventilationdetailed resultsRCT-TCZ-COVID-19, 2021 1.36 [0.39; 4.69] 1.36[0.39; 4.69]RCT-TCZ-COVID-19, 202110%126moderatenot evaluable superinfectiondetailed resultsCOVACTA (Rosas), 2020 0.77 [0.48; 1.23] 0.77[0.48; 1.23]COVACTA (Rosas), 202010%438moderatenot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2021-01-16 00:25 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 395 - roots T: 290